Orchestra BioMed Holdings Inc Ordinary Shares OBIO 深 滬
等待開盤 12-17 09:30:00 美东时间
4.46
+0.160
+3.72%
華盛通- 最 高4.5799
- 今 開4.28
- 成交量 15.18万股
- 最 低 4.28
- 昨 收 4.30
- 總市值 2.52亿
- 52周最高 6.30
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 2.20
- 委 比 61.60%
- 總股本 5646.47万
- 歷史最高 23.39
- 量 比 0.64
- 振 幅 6.97%
- 歷史最低 2.20
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces Price Target of $15.
12-11 00:03
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
11-12 23:57
Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.21 percent. This is a 2.44 percent increase over losses of $(0.41) per share
11-11 05:32
Orchestra BioMed Announces Strategic Agreement with Terumo
Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On October 28, 2...
10-28 20:26
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Orchestra BioMed and Terumo have entered into a termination and right of first refusal agreement for Virtue SAB, a drug delivery balloon system for coronary artery disease. Terumo will pay $30 million to Orchestra BioMed, including a $10 million upfront payment and a $20 million investment. Under the agreement, Terumo gains the right of first refusal to acquire or distribute Virtue SAB for coronary indications. Orchestra BioMed retains all develo...
10-28 12:00
Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus
10-27 21:04
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed Holdings, Inc. announced the initiation of the Virtue Trial, a pivotal study comparing its Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) to the AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis (ISR). Virtue SAB is a non-coated drug-eluting balloon designed to deliver a large dose of extended-release sirolimus, addressing limitations of traditional drug-coated balloons. The trial, which began enrol...
10-27 13:00
